title: Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.
abstract: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity with a high incidence of central nervous system (CNS) involvement at diagnosis. To evaluate CNS involvement, particularly recurrence including progression on therapy and relapse of IVLBCL, we retrospectively analyzed 109 patients with IVLBCL receiving chemotherapies with or without rituximab. In 82 patients (75%) without CNS involvement at initial diagnosis, risk of CNS recurrence at 3 years was 25% with a median follow-up in survivors of 39 months (range, 2-158 months). In 27 patients (25%) with CNS involvement at initial diagnosis, risk of CNS recurrence at 1 year was 25% with a median follow-up in survivors of 18 months (range, 10-77 months). Duration from diagnosis to CNS recurrence tended to be short in patients with CNS involvement at diagnosis. No significant difference in risk of CNS recurrence was found between patients receiving chemotherapies with or without rituximab. On multivariate analysis skin involvement at initial diagnosis was identified as a predictive factor for CNS recurrence in patients without CNS involvement at diagnosis (hazard ratio, 5.27; 95% confidence interval, 1.59-17.4; P = 0.007). Survival rate after CNS recurrence at 2 years was 12% in patients without CNS involvement at diagnosis. Central nervous system recurrence is a serious complication in IVLBCL patients and optimal strategies for CNS involvement should be established to obtain further improvements to clinical outcomes in the rituximab era.
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shimada
authors.forename: Takuhei
authors.initials: T
authors.lastname: Murase
authors.forename: Kosei
authors.initials: K
authors.lastname: Matsue
authors.forename: Masataka
authors.initials: M
authors.lastname: Okamoto
authors.forename: Naoaki
authors.initials: N
authors.lastname: Ichikawa
authors.forename: Norifumi
authors.initials: N
authors.lastname: Tsukamoto
authors.forename: Nozomi
authors.initials: N
authors.lastname: Niitsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miwa
authors.forename: Hideki
authors.initials: H
authors.lastname: Asaoku
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kosugi
authors.forename: Ako
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Morio
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Saburi
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Masaki
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Motoko
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Tomoki
authors.initials: T
authors.lastname: Naoe
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kinoshita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab
references.citation: Ann Oncol. 2007 Mar;18(3):541-5
references.pmid: 17164228
references.citation: Arch Neurol. 2002 Mar;59(3):439-43
references.pmid: 11890850
references.citation: Eur J Haematol. 2008 Mar;80(3):236-44
references.pmid: 18081700
references.citation: Ann Oncol. 2000 Jun;11(6):685-90
references.pmid: 10942056
references.citation: J Clin Oncol. 2008 Nov 1;26(31):5134-6; author reply 5136-7
references.pmid: 18838697
references.citation: J Clin Oncol. 2007 Jul 20;25(21):3168-73
references.pmid: 17577023
references.citation: Leuk Lymphoma. 2003 Aug;44(8):1353-9
references.pmid: 12952229
references.citation: Ann Oncol. 2004 Jan;15(1):129-33
references.pmid: 14679132
references.citation: Muscle Nerve. 2000 Aug;23(8):1295-300
references.pmid: 10918273
references.citation: Ann Oncol. 2007 Jan;18(1):149-157
references.pmid: 17018708
references.citation: Blood. 2009 Apr 23;113(17):3896-902
references.pmid: 19144985
references.citation: Cancer. 1980 Feb;45(3):545-52
references.pmid: 6986199
references.citation: Br J Haematol. 2004 Oct;127(2):173-83
references.pmid: 15461623
references.citation: Pathol Int. 2004 Apr;54(4):231-6
references.pmid: 15028023
references.citation: Blood. 1998 Feb 15;91(4):1178-84
references.pmid: 9454747
references.citation: Blood. 2007 Jan 15;109(2):478-85
references.pmid: 16985183
references.citation: J Clin Oncol. 1986 Jun;4(6):847-58
references.pmid: 3711961
references.citation: Br J Haematol. 2000 Dec;111(3):826-34
references.pmid: 11122144
references.citation: Haematologica. 2007 Apr;92(4):486-92
references.pmid: 17488659
references.citation: Leuk Lymphoma. 2003 Jun;44(6):955-62
references.pmid: 12854893
references.citation: Cancer. 2002 Aug 1;95(3):576-80
references.pmid: 12209750
references.citation: Int J Hematol. 2006 Jul;84(1):74-8
references.pmid: 16867907
references.citation: J Clin Oncol. 1983 Nov;1(11):677-81
references.pmid: 6689423
references.citation: Blood. 2008 Feb 1;111(3):1085-93
references.pmid: 17962515
references.citation: Ann Oncol. 2002 Jul;13(7):1099-107
references.pmid: 12176790
references.citation: N Engl J Med. 1993 Sep 30;329(14):987-94
references.pmid: 8141877
references.citation: Mayo Clin Proc. 2007 Dec;82(12):1525-7
references.pmid: 18053461
references.citation: J Clin Oncol. 2008 Jul 1;26(19):3189-95
references.pmid: 18506023
references.citation: Cancer. 1982 Feb 1;49(3):586-95
references.pmid: 7059915